PATRIA PRIVATE EQUITY TRUST PLC
(THE “COMPANY”)
Appointment of New Director
11 November 2026
The Board of Directors of the Company is pleased to announce the appointment of Nigel Reynolds as a Non-Executive Director with effect from 17 November 2026. It is intended that Nigel will, after a transition period, be appointed as chair of the Company’s Audit and Risk Committee, replacing Calum Thomson who will retire from the Board at the AGM in March 2027 as part of the Board’s ongoing succession planning.
In addition, Yvonne Stillhart will succeed Calum Thomson as Senior Independent Director with effect from 17 November 2026.
Nigel has 34 years of accounting and finance experience advising both listed and private companies. He was a partner at PwC for 20 years specialising in audit, transaction services and capital markets until his retirement in December 2025. During his time at PwC he led its London Assurance practice and its private equity portfolio company practice and was the relationship partner for several UK listed and international companies including investment trusts. Over his career he has also advised companies on strategy, M&A, internal audit and tax and has overseen technology, sustainability and other important projects for PwC clients.
Nigel is currently a Non-Executive Director of Biopharma Credit PLC, an investment trust which provides debt capital for the life sciences industry, and the law firm Simmons & Simmons.
There is no further information required to be disclosed under UKLR 6.4.8 of the Financial Conduct Authority Listing Rules.
For further information please contact:
Holly Kidd, Company Secretary | Holly.Kidd@patria.com |
GPMS Corporate Secretary Limited |
Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
